BioSig Technologies (NASDAQ:BSGM) Rating Increased to Buy at Zacks Investment Research

BioSig Technologies (NASDAQ:BSGMGet Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The firm currently has a $1.25 price target on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 7.76% from the company’s previous close.

According to Zacks, “BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The Company’s first product, PURE EP ™ System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. “

BSGM stock traded up $0.02 during mid-day trading on Wednesday, reaching $1.16. The company had a trading volume of 250,522 shares, compared to its average volume of 203,725. The stock has a market capitalization of $45.95 million, a P/E ratio of -0.97 and a beta of 1.70. BioSig Technologies has a one year low of $0.73 and a one year high of $4.58. The stock’s 50-day simple moving average is $1.07 and its two-hundred day simple moving average is $1.78.

BioSig Technologies (NASDAQ:BSGMGet Rating) last posted its earnings results on Thursday, March 31st. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). BioSig Technologies had a negative net margin of 9,535.04% and a negative return on equity of 232.98%. As a group, research analysts predict that BioSig Technologies will post -0.58 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of BSGM. Virtu Financial LLC bought a new stake in shares of BioSig Technologies during the fourth quarter valued at about $28,000. Advisor Group Holdings Inc. raised its stake in shares of BioSig Technologies by 31.2% during the third quarter. Advisor Group Holdings Inc. now owns 15,350 shares of the company’s stock valued at $46,000 after purchasing an additional 3,650 shares in the last quarter. Morgan Stanley raised its stake in shares of BioSig Technologies by 37.4% during the second quarter. Morgan Stanley now owns 20,575 shares of the company’s stock valued at $80,000 after purchasing an additional 5,601 shares in the last quarter. Eidelman Virant Capital acquired a new position in BioSig Technologies during the fourth quarter worth about $98,000. Finally, Stifel Financial Corp acquired a new position in BioSig Technologies during the fourth quarter worth about $109,000. Institutional investors and hedge funds own 12.27% of the company’s stock.

About BioSig Technologies (Get Rating)

BioSig Technologies, Inc, together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time.

Read More

Get a free copy of the Zacks research report on BioSig Technologies (BSGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.